173026-23-8Relevant articles and documents
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
-
Page/Page column 984-985, (2021/02/10)
The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
-
Paragraph 4472; 4473, (2016/05/02)
The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
Compounds having a benzisoselen-azoline and -azine structure, method for preparing same and therapeutic uses thereof
-
, (2008/06/13)
The invention concerns novel benzisoselen-azoline and -azine derivatives. These novel derivatives have the following general formula (II): STR1 where: R1 to R8 and R10 have various meanings, in particular H, alkyl, etc . .